Current Report Filing (8-k)
14 January 2020 - 12:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 13, 2020
LIPOCINE INC.
(Exact name of registrant as specified in
its charter)
Commission File No. 001-36357
Delaware
|
99-0370688
|
(State or other jurisdiction of incorporation)
|
(IRS Employer Identification Number)
|
|
|
675 Arapeen Drive, Suite 202
Salt Lake City, Utah 84108
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (801) 994-7383
Former name or former address, if changed
since last report: Not Applicable
______________________
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities
registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
LPCN
|
The NASDAQ Stock Market LLC
|
The Company has updated its corporate presentation that it uses
when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.
Additionally, the Company has updated its LPCN 1144 presentation
that is uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.2.
|
Item 9.01
|
Financial Statements and Exhibits.
|
The following exhibits are filed with this report:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
LIPOCINE INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
January 13, 2020
|
|
By:
|
/s/ Mahesh V. Patel
|
|
|
|
|
Mahesh V. Patel
|
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2024 to May 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2023 to May 2024